The forced swim test has poor accuracy for identifying novel antidepressants

Area of Science:

• Neuroscience
• Pharmacology
• Drug Discovery

Background:

• Treatment-resistant depression (TRD) is prevalent, yet new antidepressant development has stalled.
• Preclinical tests, like the forced swim test (FST), are criticized for low quality and over-reliance.
• Pharmaceutical companies have largely withdrawn from antidepressant research and development.

Purpose of the Study:

• To retrospectively review compounds tested in the FST by major pharmaceutical companies.
• To assess if FST results correlate with demonstrated antidepressant effects in human trials.
• To evaluate the predictive validity of the FST for novel antidepressant discovery.

Main Methods:

• Retrospective analysis of 109 compounds tested in the FST by pharmaceutical companies.
• Cross-referencing FST data with human clinical trial results for antidepressant efficacy.
• Assessing the predictive accuracy of the FST for identifying successful human antidepressants.

Main Results:

• Only 28% of FST-tested compounds were explored for human antidepressant effects.
• The FST positively predicted human antidepressant efficacy for only three compounds.
• None of the compounds showing positive FST prediction are currently approved for depression treatment.
• The FST demonstrated poor accuracy in identifying novel antidepressant candidates.

Conclusions:

• The forced swim test (FST) has limited utility as a preclinical screening tool for antidepressant drug discovery.
• The low predictive accuracy of the FST may contribute to the stagnation in antidepressant development.
• Rethinking preclinical assessment methods is crucial for advancing depression treatment.